Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester D&E
NCT07537894Phase 3Withdrawn
- Sponsor
- Stanford University
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexmedetomidine in complicated grief disorder (PGD), post-traumatic stress disorder (PTSD), sponsored by Stanford University. Planned start Jul 2026; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
complicated grief disorder (PGD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07537894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537894.